9546 Fair Value & Analysis
Healthcare · Market cap 424M SAR
Fair value as of: Jul 31, 2026
From 14 valuation models · updated today
Share price −8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 20.06 SAR – 1,000,000 SAR · fair‑value band 16.58 SAR – 27.86 SAR · the 20.20 SAR price screens below the 22.28 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
9546 (9546) currently trades at 20.20 SAR, while our model-based Fair Value estimate is 22.28 SAR, implying the stock looks roughly 10.3% undervalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, 9546 generated revenue of 202M SAR at a net margin of 13.6%. Revenue grew 5.8% year over year. It earns a return on equity of 13.0%. Net debt stands at 102M SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 16.58 SAR (bear case) to 27.86 SAR (bull case); at 20.20 SAR, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -19% fair-value upside, at 10%, 9546 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
9546 reported revenue of 202M SAR in FY2025 versus 118M SAR in FY2021, a compound +14.4%/yr. Reported net income was 27.5M SAR in FY2025, compounding +1.6%/yr from FY2021.
Is 9546 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FRE | €39.54 | €31.98 | -19% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
| DaVita Inc DVAI34 | R$1,002 | R$1,038 | +4% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,305 | ₹2,546 | -69% |
| Fresenius Medical Care AG FMSC34 | R$120.84 | R$36.43 | -70% |
| Aier Eye Hospital Group 300015 | ¥8.54 | ¥6.73 | -21% |
Compare 9546 with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 9546 overvalued or undervalued?
What is the fair value of 9546?
What is the quality score of 9546?
What is the revenue of 9546?
What is the net profit margin of 9546?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track 9546 and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.